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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is often accompanied by multiple comorbidities,
which are associated with an increased risk of exacerbation, a poor health-related quality of life, and high mortality.
However, differences in comorbidity profile by race and ethnicity in COPD patients have not been fully elucidated.
Methods: Participants aged 40 to 79 years with spirometry-defined COPD from the U.S. National Health and
Nutrition Examination Survey (NHANES) (2007–2012) and from the Korea NHANES (2007–2015) were analyzed to
compare the prevalence of comorbidities by race and ethnicity group. Comorbidities were defined using
questionnaire data, physical exams, and laboratory tests.
Results: Non-Hispanic Whites had the highest prevalence of dyslipidemia (65.5%), myocardial infarction (6.2%),
osteoarthritis (40.1%), and osteoporosis (13.6%), while non-Hispanic Blacks had the highest prevalence of asthma
(24.0%), hypertension (70.2%), stroke (7.3%), diabetes mellitus (DM) (23.3%), anemia (16.4%), and rheumatoid arthritis
(11.9%). Compared to non-Hispanic Whites, non-Hispanic Blacks had a significantly higher prevalence of
hypertension, stroke, DM, anemia, and rheumatoid arthritis after adjusting for age, sex, body mass index, and
smoking status, while Hispanics had a significantly higher prevalence of DM and anemia, and Koreans had
significantly lower prevalences of all comorbidities except stroke, DM, and anemia.
Conclusions: COPD-related comorbidities varied significantly by race and ethnicity, and different strategies may be
required for the optimal management of COPD and its comorbidities in different race and ethnicity groups.
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Background
Chronic obstructive pulmonary disease (COPD) is a
common respiratory disease characterized by persistent
respiratory symptoms and airflow limitations [1]. Due to
the ongoing epidemic of smoking and to prolonged life
expectancy, COPD is projected to increase in prevalence
and to contribute over 4.5 million annual deaths world-
wide by 2030 [2, 3].
Since aging and smoking are independent risk factors
not only for COPD, but also for multiple chronic
diseases, COPD is often accompanied by comorbidities,
including cardiovascular disease (CVD), osteoporosis,
metabolic syndrome, depression, and several types of
cancer [4]. Furthermore, in COPD patients, these co-
morbidities are associated with an increased risk of ex-
acerbation [5], a poor health-related quality of life [6],
increased utilization of health services [7], and high
mortality [8]. As a consequence, recent COPD guidelines
give special emphasis to the management of comorbid
conditions in COPD [1].
COPD guidelines, however, have been developed using
data primarily from populations of European descent.
COPD and associated comorbidities have multiple gen-
etic, behavioral, environmental, and socioeconomic risk
factors, which may vary substantially across racial
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groups, like other diseases [9–11], but differences in co-
morbidity profile by race and ethnicity in COPD patients
have not been fully elucidated. This study aimed to
evaluate differences in comorbidity profile by race and
ethnicity in subjects with COPD participating in nation-




We used data from the 2007–2012 cycles of the U.S.
National Health and Nutrition Examination Survey
(NHANES) and from the 2007–2015 cycles of the Korea
NHANES (KNHANES). Both surveys provide nationally
representative data of the non-institutionalized population
using a multi-stage cluster sampling design. We restricted
our analysis to men and women 40 to 79 years old with
spirometry-defined COPD [pre-bronchodilator forced ex-
piratory volume in 1 s (FEV1) / forced vital capacity (FVC)
< 70%] [12]. Among U.S. NHANES participants, we
further restricted the analysis to those who self-identified
as Non-Hispanic White (n = 944), Non-Hispanic Black (n
= 324), or Hispanic (n = 227). KNHANES provided a rep-
resentation of Asians (n = 3808), as the number of Asian
participants with COPD in U.S. NHANES was too small
for comparisons (Fig. 1).
Spirometric measurement
In both surveys, spirometry was performed according
to the recommendations of the American Thoracic
Society and European Respiratory Society [13]. Abso-
lute values of FEV1 and FVC were obtained, and the
percentage of predicted values for FEV1 and FVC
were calculated using the reference equation obtained
from an analysis of the general U.S. population for
U.S. NHANES [14] and a representative Korean sam-
ple for KNHANES [15].
Definitions
COPD was defined based on pre-bronchodilator FEV1 /
FVC < 0.7, and COPD severity was classified as mild
(FEV1 ≥ 80% predicted), moderate (50% ≤ FEV1 < 80%
predicted), or severe-to-very severe (FEV1 < 50% pre-
dicted) [1]. Height and weight were measured and body
mass index (BMI) was calculated as weight in kilograms di-
vided by height in meters squared. Obesity was defined as
BMI ≥ 30.0 kg/m2 and overweight was defined as BMI =
25.0–29.9 kg/m2 in Non-Hispanic Whites, Non-Hispanic
Blacks, and Hispanics, and as BMI ≥ 25 kg/m2 for obesity
and as BMI = 23.0–24.9 for overweight in Koreans accord-
ing to World Health Organization guidelines [16].
Comorbidities were defined as a self-reported phys-
ician diagnosis. In addition, hypertension was defined
as the use of antihypertensive medication, a systolic
Fig. 1 Flow chart of study participants. COPD was defined as pre-bronchodilator forced expiratory volume in 1 s / forced vital capacity < 70%.
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blood pressure ≥ 140 mmHg, or a diastolic blood pres-
sure ≥ 90 mmHg. Dyslipidemia was defined as the use
of lipid-lowering medications or a low-density lipopro-
tein cholesterol level greater than 130 mg/dL or
high-density lipoprotein cholesterol level less than
40 mg/dL [17]. Diabetes mellitus (DM) was defined as
the use of glucose-lowering medications or a fasting
plasma glucose level ≥ 126 mg/dL. Anemia was defined
as hemoglobin level < 13 g/dL in men and < 12 g/dL in
women [18].
Outcomes
We compared the comorbidity profile by race and ethni-
city in subjects with COPD participating in U.S. and
Korea NHANES. As comorbidities, we included asthma,
hypertension, dyslipidemia, stroke, myocardial infarction,
DM, and osteoporosis, which were recommended for
screening and management in the Global Initiative for
COPD guideline [1], plus anemia, osteoarthritis, and
rheumatoid arthritis (RA), three common conditions
having a substantial impact on the quality of life.
Statistical analysis
Statistical analysis used the svy commands in Stata (release
13.1; StataCorp LP, College Station, TX, USA) to account
for survey weights and for the complex sampling design.
For each comorbidity, we calculated its prevalence and
95% confidence interval (CI) by race and ethnicity group
and used log binomial regression to estimate adjusted
prevalence ratios (aPRs) and 95% CIs comparing each race
and ethnicity group to Non-Hispanic Whites, adjusting
for age, sex, BMI, and smoking status.
Table 1 Characteristics of participants with COPD aged 40–79 by race and ethnicity, U.S. NHANES 2007–2012 and Korea NHANES 2007–
2015a
U.S. NHANES Korea NHANES
Non-Hispanic White (n = 944) Non-Hispanic Black (n = 324) Hispanicb (n = 227) Korean (n = 3808) p value
Age, years 59.8(0.4) 59.6 (0.7) 59.6 (0.8) 63.6 (0.2) < 0.001
Age group, years < 0.001
40–49 18.7 (1.7) 20.7 (2.9) 19.7 (3.1) 11.3 (0.7)
50–59 31.2 (2.2) 30.9 (2.6) 29.9 (3.9) 23.2 (0.9)
60–69 30.3 (2.4) 24.1 (1.8) 32.0 (3.0) 31.2 (0.9)
70–79 19.8 (1.3) 24.2 (2.5) 18.3 (2.7) 34.3 (1.0)
Men, % 59.1 (2.4) 60.2 (2.3) 69.2 (4.2) 73.8 (0.9) < 0.001
BMI, kg/m2 27.7 (0.2) 27.8 (0.4) 28. 6 (0.4) 23.7 (0.1) < 0.001
BMI group 0.023
Underweight 1.9 (0.5) 3.1 (1.2) 0 2.7 (0.4)
Normal 32.3 (1.6) 35.1 (2.8) 27.4 (3.4) 38.9 (1.1)
Overweight 37.8 (1.5) 33.4 (2.3) 41.9 (3.7) 27.6 (0.9)
Obese 27.9 (1.4) 28.4 (2.6) 30.7 (3.8) 30.7 (1.0)
Smoking < 0.001
Current 33.5 (2.4) 42.4 (3.4) 26.4 (2.8) 41.6 (1.0)
Former 39.9 (2.1) 26.4 (2.2) 35.5 (2.9) 27.9 (0.9)
Never 26.6 (2.1) 31.3 (2.8) 38.1 (3.3) 30.5 (1.0)
Spirometry
FVC, % predicted 96.5 (0.7) 96.7 (1.1) 97.9 (1.4) 90.5 (0.3) < 0.001
FEV1, % predicted 80.3 (0.7) 77.5 (1.1) 82.6 (1.3) 77.8 (0.3) < 0.001
COPD severityc 0.106
Mild 52.3 (2.3) 46.5 (3.1) 60.4 (4.1) 46.4 (1.0)
Moderate 41.3 (2.2) 44.4 (3.1) 36.0 (4.3) 48.7 (1.1)
Severe-to-very severe 6.4 (0.8) 9.2 (2.3) 3.6 (1.1) 4.9 (0.4)
aValues are presented as weighted means (standard error of the mean) or weighted percentage (standard error of the percentage)
bHispanic was defined as Mexican American or other Hispanic
cParticipants were categorized as having mild (FEV1 / FVC < 0.7 and FEV1 ≥ 80% predicted), moderate (FEV1 / FVC < 0.7 and 50% ≤ FEV1 < 80% predicted),
or severe-to-very severe (FEV1 / FVC < 0.7 and FEV1 < 50% predicted) disease based on the Global Initiative for Chronic Obstructive Lung Disease guideline
COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey (NHANES), BMI body mass index, FEV1 forced expiratory
volume in 1 s, FVC forced expiratory vital capacity
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Results
The average age of non-Hispanic Whites, non-Hispanic
Blacks, and Hispanics was similar (59.8, 59.6, and
59.6 years, respectively), but Koreans were older on aver-
age (63.6 years, p < 0.001; Table 1). By sex, the propor-
tions of men among non-Hispanic Whites and
non-Hispanic Blacks were similar (59.1 and 60.2%, re-
spectively), and lower than among Hispanic (69.2%) and
Korean (73.8%) participants. Hispanic participants were
the most likely to be overweight or obese (72.6%), while
Non-Hispanic Blacks and Koreans were the most likely
to be current smokers (42.4 and 41.6%, respectively). By
severity, non-Hispanic Blacks had the highest proportion
of severe-to-very-severe COPD (9.2%), while Hispanics
had the lowest (3.6%).
Non-Hispanic White participants had the highest
prevalence of dyslipidemia (65.5%), myocardial infarction
(6.2%), osteoarthritis (40.1%), and osteoporosis (13.6%),
while non-Hispanic Blacks had the highest prevalence of
asthma (24.0%), hypertension (70.2%), stroke (7.3%), DM
(23.3%), anemia (16.4%), and RA (11.9%) (Table 2 and
Fig. 2). Hispanics had very high prevalences of all co-
morbidities except for stroke, ranking second in the
prevalence of asthma, hypertension, myocardial infarc-
tion, DM, anemia, RA, and osteoporosis compared to
other race and ethnicity groups. Koreans had the lowest
prevalence of all comorbidities except for stroke, DM,
and anemia.
Compared to non-Hispanic Whites, non-Hispanic
Black participants had a significantly higher prevalence
of hypertension (aPR 1.36, 95% CI 1.23 to 1.51), stroke
(aPR 2.01, 95% CI 1.16 to 3.47), DM (aPR 1.76, 95% CI
1.34 to 2.31), anemia (aPR 3.82, 95% CI 2.42 to 6.04),
and RA (aPR 1.83, 95% CI, 1.16 to 2.89) after adjusting
for age, sex, BMI, and smoking status, while Hispanics
had a higher prevalence of DM (aPR 1.64, 95% CI 1.18
to 2.29) and anemia (aPR 2.18, 95% CI 1.23 to 3.86).
Koreans had significantly lower prevalences of all
comorbidities except stroke, DM, and anemia (Table 3).
Discussion
We found major differences in the comorbidity profile
among race and ethnicity groups in subjects with COPD.
Non-Hispanic Whites had a comorbidity pattern charac-
terized by dyslipidemia, myocardial infarction, osteoarth-
ritis, and osteoporosis. Non-Hispanic Blacks had a high
prevalence of current smokers as well as a high prevalence
of multiple comorbidities, especially asthma, hypertension,
stroke, DM, anemia, and RA. Hispanics had the highest
average BMI levels, as well as high prevalences of asthma
and DM. Finally, Koreans had the highest prevalence of
current smokers, but lower prevalences of other comor-
bidities except for stroke, DM, and anemia. Given that
coexisting comorbidities have an adverse impact on
COPD prognosis, early recognition and management of
prevalent disease based on racial differences could reduce
the clinical burden of disease in COPD patients.
CVD is a key comorbidity in COPD patients and a
major determinant of mortality and functional status
[19]. In our study, non-Hispanic Whites had a pattern
of CVD comorbidities characterized by a high preva-
lence of dyslipidemia and coronary disease, while
non-Hispanic Blacks had a pattern driven by hyper-
tension, DM, and stroke. These were like the results
of a previous study that compared COPD
Table 2 Prevalence of comorbidities (95% confidence intervals) among participants with COPD aged 40–79 by race and ethnicity,
U.S. NHANES 2007–2012 and Korea NHANES 2007–2015
U.S. NHANES Korea NHANES
Non-Hispanic White (n = 944) Non-Hispanic Black (n = 324) Hispanica (n = 227) Korean (n = 3808) P value
Asthma 19.9 (16.5 to 23.7) 24.0 (19.4 to 29.3) 20.7 (14.3 to 29.0) 9.1 (8.0 to 10.4) < 0.001
Cardiovascular disease
Hypertension 51.5 (47.4 to 55.7) 70.2 (64.0 to 75.6) 54.1 (46.4 to 61.5) 48.8 (46.8 to 50.8) < 0.001
Dyslipidemia 65.5 (61.2 to 69.7) 53.9 (47.3 to 60.3) 57.2 (48.5 to 65.4) 44.8 (42.7 to 47.0) < 0.001
Stroke 3.6 (2.6 to 4.8) 7.3 (4.6 to 11.3) 1.6 (0.5 to 5.3) 2.5 (2.0 to 3.1) 0.003
Myocardial infarction 6.2 (4.7 to 8.1) 4.2 (2.6 to 6.6) 5.4 (3.3 to 8.8) 1.7 (1.2 to 2.3) < 0.001
Diabetes mellitus 13.3 (10.8 to 16.4) 23.3 (18.6 to 28.8) 23.1 (17.5 to 29.7) 18.4 (16.8 to 20.1) < 0.001
Anemia 4.4 (3.0 to 6.3) 16.4 (12.3 to 21.6) 9.2 (5.8 to 14.3) 6.6 (5.7 to 7.6) < 0.001
Musculoskeletal disease
Osteoarthritis 40.1 (36.4 to 44.0) 38.0 (33.0 to 43.2) 31.2 (24.5 to 38.8) 14.9 (13.5 to 16.5) < 0.001
Rheumatoid arthritis 6.3 (4.3 to 9.1) 11.9 (8.4 to 16.4) 7.9 (5.2 to 12.0) 2.2 (1.6 to 2.8) < 0.001
Osteoporosis 13.6 (10.9 to 16.9) 9.1 (6.5 to 12.7) 9.9 (6.1 to 15.4) 3.3 (2.7 to 4.1) < 0.001
aHispanic was defined as Mexican American or other Hispanic
COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey
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comorbidities between non-Hispanic Whites and
non-Hispanic Blacks [20]. In comparison, Hispanics
had a pattern driven by obesity and DM. In addition
to CVD, asthma is a major comorbidity as well as a
risk factor in COPD, complicating treatment and fur-
ther impairing functional status. Asthma prevalence
was particularly high among non-Hispanic Blacks, al-
though non-Hispanics Whites and Hispanics also had
a relatively high prevalence. Considering their high
prevalence and disease burden, clinicians should con-
sider active screening and management of CVD and
asthma in COPD patients.
Anemia has recently been recognized as an independ-
ent prognostic predictor of increased hospitalization and
mortality in COPD [21–24]. It is also an important co-
morbidity linked to nutritional deficiency and poor exer-
cise performance among COPD patients [23]. Previous
studies have suggested the possibility of improving
functional outcomes by correcting anemia [25, 26], and
active screening and management of anemia among
COPD patients may be beneficial for clinical outcomes,
especially among non-Hispanic Blacks and Hispanics.
Non-Hispanic Blacks had very high prevalences of
COPD risk factors and comorbidities. Multiple sources
of health disparities and inequalities, including socio-
economic factors, environmental hazards, behavioral
factors, and access to health care and preventive ser-
vices, contribute to the excess burden of disease and
mortality among non-Hispanic Blacks in the U.S. [27].
The presence of multiple comorbidities may further
complicate management and prognosis in these pa-
tients [28, 29]. It may be necessary, however, to develop
integrated approaches to prevention and management
to reduce the burden of chronic disease-related mor-
bidity and mortality, particularly among non-Hispanic
Black subjects with COPD.
Fig. 2 Prevalence of comorbidities among participants with COPD aged 40–79 by race and ethnicity, U.S. NHANES 2007–2012 and Korea NHANES
2007–2015. COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey
Lee et al. BMC Medicine  (2018) 16:178 Page 5 of 8
Hispanic subjects with COPD had a very high burden
of overweight and obesity and DM, although the preva-
lence of myocardial infarction was lower than in
non-Hispanic Whites. The lower prevalence of CVD,
despite relatively high levels of metabolic risk factors
among Hispanics, has been termed the Hispanic paradox
[30], but the reasons for this paradox are controversial.
Irrespective of the implications of elevated BMI in His-
panic patients, the high prevalence of overweight and
obesity in this group should prompt proper manage-
ment, as morbid obesity is a risk for poor management
and functional decline in COPD [31, 32].
Finally, although Korean COPD patients were older,
more likely to be smokers, and more likely to be male
than other race or ethnicity groups, they had the lowest
prevalences of most comorbidities. A similar pattern has
been observed in other Asian countries [33]. In particu-
lar, the low prevalence of myocardial infarction in
Koreans may reflect lower background rates of the dis-
ease due to environmental or genetic factors. Since
smoking is a predominant risk factor for COPD among
Asians and considering the increasing number of Asians
in the U.S., more active surveillance regarding COPD
and its comorbidities may be warranted.
Several limitations need to be considered when interpret-
ing our findings. First, we used a cross-sectional study and
we do not have information on the timing of the develop-
ment of each comorbidity. We were, thus, unable to estab-
lish causal inferences. Our objective, however, was to
compare the comorbidity patterns across race and ethnicity
groups, not to identify causal pathways of comorbidities.
The different comorbidity patterns may be due to different
prevalences of risk factors such as smoking, obesity, socio-
economic status, or environmental exposures, but race and
ethnicity may affect the development of comorbidities. Sec-
ond, we could not evaluate the prevalence of some import-
ant COPD-related comorbidities or conditions, such as
obstructive sleep apnea or use of long-term oxygen ther-
apy, due to lack of data in either U.S. NHANES or
KNHANES. Third, we did not have data that would allow
us to evaluate the outcomes of the different comorbidities.
This information is important for understanding the im-
pact of the differences in comorbidity profile by race and
ethnicity. Given the racial differences in outcomes such as
emergency room visits and duration of hospital stays [7],
further studies should evaluate the management and out-
comes of COPD, including exacerbations and mortality, by
comorbidity profile. Fourth, we used data for Koreans as
we did not have data for other Asian groups. However, Ko-
rean COPD patients had similar overall characteristics as
other Asian COPD patients, including Taiwanese, Japanese,
or Chinese patients, although the degree of exposure to
biomass fuels differed across Asian groups [33].
Conclusions
In our study, COPD-related comorbidities occurred dis-
proportionally according to race and ethnicity, and differ-
ent strategies may be required for the optimal
management of COPD and its comorbidities for different
race and ethnicity groups. Furthermore, the generation of
local maps of COPD-related comorbidities may help in
planning different strategies for the diagnosis, treatment,
and prevention of COPD and its associated comorbidities.
Table 3 Adjusted prevalence ratios and 95% confidence intervals for comorbidities in participants with COPD aged 40–79, U.S.
NHANES 2007–2012 and Korea NHANES 2007–2015a
U.S. NHANES Korea NHANES
Non-Hispanic White (n = 944) Non-Hispanic Black (n = 324) Hispanicb (n = 227) Korean (n = 3808)
Asthma Reference 1.23 (0.92 to 1.65) 1.05 (0.72 to 1.53) 0.56 (0.43 to 0.72)
Cardiovascular disease
Hypertension Reference 1.36 (1.23 to 1.51) 1.03 (0.89 to 1.20) 0.88 (0.81 to 0.95)
Dyslipidemia Reference 0.83 (0.72 to 0.96) 0.86 (0.73 to 1.00) 0.68 (0.63 to 0.73)
Stroke Reference 2.01 (1.16 to 3.47) 0.47 (0.14 to 1.61) 0.69 (0.45 to 1.06)
Myocardial infarction Reference 0.66 (0.39 to 1.12) 0.86 (0.49 to 1.53) 0.21 (0.14 to 0.33)
Diabetes mellitus Reference 1.76 (1.34 to 2.31) 1.64 (1.18 to 2.29) 1.11 (0.90 to 1.38)
Anemia Reference 3.82 (2.42 to 6.04) 2.18 (1.23 to 3.86) 1.31 (0.90 to 1.91)
Musculoskeletal disease
Osteoarthritis Reference 0.95 (0.82 to 1.10) 0.81 (0.65 to 1.01) 0.35 (0.30 to 0.40)
Rheumatoid arthritis Reference 1.83 (1.16 to 2.89) 1.40 (0.85 to 2.31) 0.31 (0.20 to 0.50)
Osteoporosis Reference 0.68 (0.45 to 1.03) 0.74 (0.46 to 1.20) 0.22 (0.16 to 0.32)
aAdjusted for age, sex, BMI group (underweight, normal, overweight, or obese using World Health Organization criteria for the U.S. population and Asian criteria
for the Korean population), and smoking status (current, former, or never)
bHispanic was defined as Mexican American or other Hispanic
COPD chronic obstructive pulmonary disease, NHANES National Health and Nutrition Examination Survey
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